A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

To join this study, you generally need to be at least 18 years old. If you have multiple myeloma, your medical records must clearly show that you have the disease and that it can be measured, for example, by certain protein levels in your blood or urine. You also need to have experienced your multiple myeloma getting worse either during or within two months of your most recent treatment.

Your general health and how well you can perform daily activities will also be checked. This is measured using a system called ECOG, and you would typically need a score of 0, 1, or 2, which means you're fairly active and able to look after yourself. If you are newly diagnosed, your doctor will confirm your diagnosis based on specific criteria agreed upon by experts, which includes looking at the cancer cells in your bone marrow and checking for certain problems like high calcium, kidney issues, anaemia, or bone damage.

There are also specific checks related to the level of cancer cells in your bone marrow or certain markers in your blood. These help the doctors make sure the study includes people who are most likely to benefit from or help us understand this new treatment. The study team will review all your medical information carefully to see if you fit the criteria.

If you decide to join this study, you'll be part of a team effort to find new ways to treat multiple myeloma. Initially, you might receive CC-220 on its own or in combination with other existing treatments like dexamethasone, daratumumab, bortezomib, or carfilzomib. The doctors will start with a specific dose, and for some patients, this might be adjusted if it's not well-tolerated. For example, the starting dose of dexamethasone might depend on your age.

You will have regular appointments for check-ups and assessments. These visits will include tests to track your health and how the treatment is working. For some people, if their condition gets worse while on CC-220 alone, they might have the option to add dexamethasone to their treatment, after discussing it with the study doctor. Treatment will continue for as long as it's helping and you're not experiencing severe side effects, or until you decide you no longer wish to continue. If your condition improves or stabilises, but you stop the main study treatment for reasons other than the cancer progressing, you will still be followed up regularly to check on your condition, usually every 21 or 28 days.